Arcutis Biotherapeutics (ARQT) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Arcutis Biotherapeutics (ARQT) right now is Multi-indication ZORYVE expansion: ZORYVE has moved from a single plaque-psoriasis cream to a franchise spanning psoriasis, seborrheic dermatitis, and atopic dermatitis across creams and a foam. 2026 revenue guidance is ~$480-495 million. If that keeps playing out, the setup is favourable; the risk to it is the dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. No one can predict where ARQT trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Arcutis Biotherapeutics (ARQT) higher?
1. Multi-indication ZORYVE expansion
ZORYVE has moved from a single plaque-psoriasis cream to a franchise spanning psoriasis, seborrheic dermatitis, and atopic dermatitis across creams and a foam. Each new FDA-approved indication and each step down in age (now into young children, with an infant atopic dermatitis filing) widens the addressable prescriber base off one familiar molecule. This multi-indication strategy is the core engine behind roughly 90%-plus annual revenue growth.
2. Revenue growth reaching profitability
Net product sales grew to about $372 million in 2025, and the company reported net income of roughly $17 million in Q4 2025 with positive operating cash flow, its first profitable quarter. Management guided 2026 revenue to roughly $480 to $495 million. Reaching self-funded profitability would reduce reliance on dilutive financing and mark a durable shift from cash-burning launch mode.
3. Payer coverage and prescriber reach
A large part of the growth has come from expanding commercial and Medicare coverage plus an enlarged dermatology sales force targeting higher-volume prescribers. Broader formulary access lowers patient out-of-pocket cost and improves the gross-to-net economics that turn prescriptions into recognized revenue. Continued coverage wins and better prescriber call frequency are key levers for converting demand into reported sales.
4. Pipeline and label depth
Beyond current approvals, Arcutis is pursuing further ZORYVE label expansions (younger pediatric psoriasis and infant atopic dermatitis) and evaluating additional roflumilast and dermatology assets. Guideline recommendations from dermatology bodies support adoption. This gives the franchise a longer runway, though the pipeline remains concentrated around a single mechanism rather than a broadly diversified portfolio.
What could weigh on ARQT?
The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. Profitability is early and inconsistent, with Q1 2026 returning to a small loss on seasonality and reinvestment, and the business carries a large accumulated deficit built up over its pre-commercial years. Competition is real, including Incyte's Opzelura (a JAK-inhibitor cream), Dermavant's Vtama (tapinarof), generic topical steroids, and systemic biologics like Dupixent in atopic dermatitis. Gross-to-net adjustments, rebates, and inventory timing can make quarterly revenue lumpy, and continued sales-force and marketing spend can keep operating results volatile even as demand grows.
Where ARQT trades today
A forecast starts from where the stock actually is. These are ARQT's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for ARQT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a ARQT forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ARQT guide and whether ARQT is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ARQT outlook
The bottom line: what is driving Arcutis Biotherapeutics (ARQT) is Multi-indication ZORYVE expansion, with 2026 revenue guidance at ~$480-495 million. If that keeps playing out the setup is favourable; the risk is the dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. No one can predict the price, so treat any ARQT forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ARQT with Walnut
Use Arcutis Biotherapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Arcutis Biotherapeutics (ARQT)?
+
No one can reliably predict where ARQT will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Arcutis Biotherapeutics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ARQT higher?
+
The main growth drivers are Multi-indication ZORYVE expansion; Revenue growth reaching profitability; Payer coverage and prescriber reach. Whether they play out is the real question, not a guaranteed path.
What are the risks to ARQT?
+
The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. Profitability is early and inconsistent, with Q1 2026 returning to a small loss on seasonality and reinvestment, and the business carries a large accumulated deficit built up over its pre-commercial years. Competition is real, including Incyte's Opzelura (a JAK-inhibitor cream), Dermavant's Vtama (tapinarof), generic topical steroids, and systemic biologics like Dupixent in atopic dermatitis. Gross-to-net adjustments, rebates, and inventory timing can make quarterly revenue lumpy, and continued sales-force and marketing spend can keep operating results volatile even as demand grows.
Will ARQT stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Arcutis Biotherapeutics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ARQT a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ARQT "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is Arcutis growing?
+
ZORYVE net sales grew to roughly $372 million in 2025, up about 123% year over year, and management guided 2026 revenue to roughly $480 to $495 million. Growth has been driven by new indications, broader age labels, and expanding payer coverage.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.